Developmental Funds are essential to the ability of the HDFCCC to pursue its strategic goals. The HDFCCC aims to focus its efforts around the two pillars of precision cancer medicine and precision population health, and CCSG funds have been used to support pilot projects and recruitments directly tied to these areas. As detailed below, recently funded pilot projects have explored areas such as the contribution of population- specific environmental factors and genetic factors to susceptibility of esophageal cancer in Tanzania; the possibility that unstudied genetic mutations in glioblastoma can be evaluated as therapeutic targets or predictive biomarkers; and the feasibility of appropriate genetic testing for individuals affected by cancer. Similarly, CCSG funds have been used to support recruitments in key areas of strategic importance to the HDFCCC, such as genomics and cancer; racial, ethnic, and geographic disparities in cancer; and discovery of prognostic and predictive biomarkers and targeted treatments for therapy-resistant disease. Use of these funds is tightly linked to the formal planning and evaluation activities of the HDFCCC to ensure that deployment of funds aligns with HDFCCC-wide strategic plans and leadership priorities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-20
Application #
9773942
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-06-01
Budget End
2020-05-31
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794

Showing the most recent 10 out of 192 publications